Compare Medtronic PLC (MDT) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs S&P Global Inc — how do they compare? Medtronic PLC trades at $82.67 (market cap $106.61B), while S&P Global Inc trades at $432.88 (market cap $132.71B). The key difference: S&P Global Inc is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| MDT | SPGI | |
|---|---|---|
Market Cap | $106.61B | $132.71B |
Sector | Health | Financials |
52-Week High | $105.35 | $534.79 |
52-Week Low | $73.75 | $370.42 |
Enterprise Value | $125.36B | $144.68B |
Dividend Yield | 3.46% | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
S&P Global (SPGI) trades at $449.75, down 0.24% on the day, with a bullish technical outlook and strong fundamentals. The stock shows robust profitability with a 30.36% net income margin and consistent revenue growth, reaching $15.34B in 2025. Recent corporate actions include the spinoff of Mobility Global, streamlining operations. Analyst consensus is strongly bullish with a $531.11 price target, and technical indicators signal a buy from moving averages despite overbought RSI levels.
The outlook for SPGI is positive, driven by margin expansion targets, AI-driven growth in API usage, and resilient recurring revenues. Key risks include high valuation multiples and sensitivity to debt issuance cycles. Investment opportunity lies in its market-leading position and strategic focus post-spinoff, though investors should monitor execution on growth initiatives and macroeconomic factors affecting capital markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
